RECLAIM STUDY: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
Latest Information Update: 04 Aug 2026
At a glance
- Drugs Pemvidutide (Primary)
- Indications Alcoholism
- Focus Therapeutic Use
- Acronyms RECLAIM
- Sponsors Altimmune
Most Recent Events
- 31 Jul 2026 Status changed from active, no longer recruiting to completed.
- 28 Jul 2026 According to an Altimmune media release, company will host a conference call and webcast at 8:00 a.m ET today to discuss the RECLAIM topline data.
- 28 Jul 2026 According to an Altimmune media release, results from the RECLAIM trial will be submitted for presentation at a forthcoming medical conference and for publication in a peer-reviewed journal.